EXPERT OPINION ON EMERGING DRUGS

简称 EXPERT OPIN EMERG DR ·ENGLAND ·出版周期 Quarterly ·年均收录 33 篇

2.7

最新影响因子

0.00%

自引率

较易

投稿难度

>12周，或约稿

审稿周期

期刊简介

EXPERT OPINION ON EMERGING DRUGS是一本专注于新兴药物研究的国际期刊，ISSN号为1472-8214，由英国出版商TAYLOR & FRANCIS LTD出版，出版地为英国，出版周期为季刊。该期刊的影响因子根据最新数据为3.1，属于非开放获取（非OA）期刊，被SCI收录，中科院分区为医学大类3区。杂志的发文特点集中于药物研发的早期阶段，涵盖药物发现、临床前研究、临床试验设计及新兴治疗方法的评估，研究领域包括小分子药物、生物制剂、基因治疗和个性化医疗等。杂志的质量较高，文章多由领域内专家撰写，具有权威性，但作为新兴药物领域的期刊，其研究内容可能涉及较高的不确定性和风险，读者需结合最新临床数据谨慎参考。

影响因子趋势

近期发表

Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics 2026-09-05

Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs 2026-07-17

Drug discovery progress in targeting the renin–angiotensin–aldosterone system for heart failure 2026-07-17

At the forefront of gene-based therapies in Dravet syndrome 2026-06-10

Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas 2026-07-15

σ <sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option? 2026-06-29

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease 2026-06-20

Obefazimod (ABX464) for moderate-to-severe Crohn’s disease: clinical development of a novel oral therapeutic approach 2026-06-20

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond 2026-06-18

Acute management of adult MOG antibody–associated disease: therapeutic choices and clinical outcomes 2026-06-13